{"id":"NCT02174627","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-26","primaryCompletion":"2018-10-04","completion":"2018-10-04","firstPosted":"2014-06-25","resultsPosted":"2019-12-16","lastUpdate":"2019-12-16"},"enrollment":2781,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Roxadustat","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Roxadustat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis","primaryOutcome":{"measure":"Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52","timeFrame":"Baseline (Day 1, Week 0) and Week 28 to Week 52.","effectByArm":[{"arm":"Roxadustat","deltaMin":1.75,"sd":0.033},{"arm":"Placebo","deltaMin":0.4,"sd":0.034}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":359,"countries":["United States","Argentina","Brazil","Bulgaria","Canada","Colombia","Czechia","Germany","Hungary","India","Malaysia","Mexico","Peru","Philippines","Poland","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","Vietnam"]},"refs":{"pmids":["36005278","34362786","33568383"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00001&amp;attachmentIdentifier=e591fa4d-7259-4500-bf4c-783f4239fab9&amp;fileName=D5740C00001_redacted_CSP_from_PRS.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00001&amp;attachmentIdentifier=cf047ffd-547d-4bee-b970-58c377627038&amp;fileName=D5740C00001_SAP-v3_Redacted_28-Sep-2018.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":795,"n":1384},"commonTop":["Hypertension","Diarrhoea","Oedema peripheral","Urinary tract infection","Nausea"]}}